Galectin Therapeutics (GALT) Interest Coverage Ratio Growth (3y) (2021 - 2026)
Powered by 
Analysis
Galectin Therapeutics (GALT) Interest Coverage Ratio Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 29.79% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -44.22% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 33.30% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -35.50% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 81.16% |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - | 47.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47.65% |
| Mar 31, 2026 | 54.98% |
| Dec 31, 2025 | 63.09% |
| Sep 30, 2025 | 57.57% |
| Jun 30, 2025 | 60.17% |
| Mar 31, 2025 | 53.05% |
| Dec 31, 2024 | 35.86% |
| Sep 30, 2024 | 56.61% |
| Jun 30, 2024 | 54.81% |
| Mar 31, 2024 | 68.27% |
| Dec 31, 2023 | 68.35% |
| Sep 30, 2023 | 65.59% |
| Jun 30, 2023 | 63.74% |
| Mar 31, 2023 | 48.32% |
| Dec 31, 2022 | 47.30% |
| Sep 30, 2022 | 38.55% |
| Jun 30, 2022 | 34.67% |
| Mar 31, 2022 | 25.91% |
| Dec 31, 2021 | 9.89% |
| Sep 30, 2021 | -34.09% |